Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

73 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-08-31

Study Completion Date

2014-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to understand if small proteins found on the surface of myeloma cells (called CXCR4 and CD47) or inside the myeloma cells (Pim kinases, sphingolipids, and pS6) can predict how patients will respond to chemotherapy-treatment and if a small molecule inside the myeloma cells (called Pim kinase) can be used as a treatment target for myeloma. A sample from the bone marrow biopsy (a small amount of tissue removed from the body for laboratory testing) and aspirate (a small amount of fluid is removed from the body for laboratory testing) that had been done before the subject entered this study will be provided for research purposes. Based on preliminary data, it is hypothesized that CXCR4, CD47, sphingolipids, and Pim kinases could be used as prognostic/predictive markers and that Pim kinase inhibitors provide a new agent for the treatment of multiple myeloma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study Of Circulating Multiple Myeloma Cells As A Biomarker of MGUS And SMM

NCT01958528

a Diagnosis of MGUS or SMM by IMWG Criteria

COMPLETED

Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma

NCT02726750

Monoclonal Gammopathy of Undetermined Significance Smoldering Plasma Cell Myeloma

RECRUITING

Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile

NCT01454297

Multiple Myeloma

COMPLETED

S0334 Analyzing Chromosomes in Patients With Newly Diagnosed Multiple Myeloma or Other Blood Disease

NCT00898066

Lymphoma Multiple Myeloma and Plasma Cell Neoplasm Precancerous/Nonmalignant Condition

COMPLETED

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

NCT02269592

Monoclonal Gammopathy of Undetermined Significance (MGUS) Myelodysplastic Syndromes Hematological Malignancies +5 more

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Myeloma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Multiple Myeloma subjects with bone marrow aspirate/biopsy

All patients seen at MUSC with a diagnosis of multiple myeloma or possible multiple myeloma who undergo bone marrow aspirate and biopsy will be approached for participation in this study.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* A diagnosis of multiple myeloma or possible multiple myeloma who will have a bone marrow biopsy and aspirate
* Planned therapy with standard chemotreatment for multiple myeloma
* Laboratory data such as calcium, beta 2-microglobulin, albumin, creatinine and bone survey available for staging purpose.
* ≥18 years old